AI illustration · not actual product photoDetails from the source.
This catalogue entry records Melanotan II, 10 mg × 10 vials (SKU ML10), using the supplied source listing. The cited dossier describes: Research has examined melanogenesis/pigmentation and melanocortin biology. Small early human studies evaluated pigmentation and sexual/erectile responses. Animal work also examined food intake and body-weight effects via central melanocortin pathways. These are research topics, not established uses or product claims. It also distinguishes available human evidence, limitations, safety concerns, and regulatory context. It does not verify this supplier-specific item’s identity, formulation, lot quality, or approval. This is not medical advice, a treatment recommendation, or authorization for human use.
- Catalogue code
- ML10
- Source specification
- 10mg*10vials
- Source document
- PriceList(1).pdf, page 1
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
The catalogue label is reproduced exactly. In published research, Melanotan-II (MT-II) is a synthetic cyclic heptapeptide analog of α-MSH, so the research compound is a peptide. The source label does not verify that the supplier-specific ML10 vial contains this compound or establish its salt form, purity, manufacturer, or composition. The supplied PDF lists SKU ML10, *10vials, price 48 per 10 vials; currency is not stated.
Biological mechanism
MT-II is a potent, non-selective agonist at melanocortin receptors MC1R, MC3R, MC4R, and MC5R. MC1R signaling in skin melanocytes is involved in pigmentation. Central MC3R/MC4R pathways are involved in energy regulation, and MC4R is linked to sexual function. These receptor-level and preclinical findings do not establish clinical benefits for people or for this vial. [2] [3]
Research focus
Research has examined melanogenesis/pigmentation and melanocortin biology. Small early human studies evaluated pigmentation and sexual/erectile responses. Animal work also examined food intake and body-weight effects via central melanocortin pathways. These are research topics, not established uses or product claims. [2] [3] [4]
Potential applications in the evidence
Investigated experimentally for effects on skin pigmentation and, in small early human studies, erectile responses and sexual desire. Animal studies have explored appetite and energy regulation. Evidence does not establish safe or effective routine tanning, treatment of erectile dysfunction or any other disease, or prevention of sun damage or skin cancer. [2] [3] [4]
Human evidence
A pilot phase-I study in three healthy men reported increased pigmentation in two participants and effects including nausea, fatigue/somnolence, yawning/stretching, and spontaneous erections. A separate small double-blind crossover report involving 20 men with erectile dysfunction described erectile responses and sexual-desire reports, with nausea and yawning frequently reported. These small, early studies with limited follow-up do not establish reliable efficacy, long-term safety, generalizability, or the identity or performance of this catalogue vial. [2] [4]
Known and potential effects
Early human studies reported increased pigmentation, nausea, yawning/stretching, fatigue or somnolence, and spontaneous erections. FDA material concerning compounded MT-II describes case reports of melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. These reports are safety signals and do not establish causation or incidence. [2] [5]
Safety and contraindications
The evidence is insufficient to establish a comprehensive contraindication list or safe-use profile. FDA notes potential immunogenicity concerns for certain routes of compounded MT-II due to aggregation or peptide-related impurities; this does not establish that the catalogued item is compounded. An Australian regulator reported inconsistent contents among a specific set of seized nasal spray bottles; that finding is not product-specific evidence about these vials. The catalogue provides no manufacturer, lot, assay, formulation source, or quality documentation, so identity, contents, and quality cannot be verified. [5] [6]
U.S. FDA / regulatory status
FDA's official record characterizes Melanotan II marketed by a particular company as an unapproved new drug and recounts FDA's position that an approved application was required for that product's marketing in interstate commerce. No FDA approval for MT-II was identified in sources reviewed as of 2026-10-30. This does not verify the regulatory status of the supplier-specific ML10 vial: the catalogue provides no manufacturer, lot, formulation source, jurisdiction, or approval documentation. Approval of another melanocortin medicine or related peptide would not transfer to this item. Do not describe this vial as FDA-approved, compounded, or research-only without reliable documentation establishing that status. [1] [5]
Evidence limitations
Human evidence is limited to small, early studies with narrow populations and short follow-up. It does not establish long-term safety, routine tanning efficacy, disease treatment, skin-cancer prevention, or the quality or composition of this exact vial. Mechanistic and animal findings are not proof of human benefit. The catalogue entry is a single named item, not a blend, and no combination evidence is relevant. [2] [3] [4]
Supporting sources
- Notice of Opportunity for Hearing (NOOH) Manookian, Edward 8/5/16 U.S. Food and Drug Administration (FDA) · Official regulatory record. Supports: FDA's historical characterization of a specific marketed Melanotan II product as an unapproved new drug and the regulatory approval requirement described in that record; it does not establish the identity/status of this supplier vial.
- Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study PubMed / National Library of Medicine; Life Sciences (1996) · Primary human phase-I study. Supports: MT-II peptide description, a three-participant human pilot, observed pigmentation and reported short-term effects.
- Bench-Top to Clinical Therapies: A Review of Melanocortin Ligands PubMed Central / peer-reviewed review (2017) · Peer-reviewed review. Supports: MT-II structure and non-selective MC1R/MC3R/MC4R/MC5R agonism; distinguishes preclinical melanocortin research and receptor roles.
- Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II PubMed / National Library of Medicine; International Journal of Impotence Research (2000) · Human clinical study report/review. Supports: Small human crossover evidence involving men with erectile dysfunction and reported effects/adverse effects.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration (FDA) · Official safety information. Supports: FDA's concerns specifically about compounded MT-II preparations, including potential immunogenicity and case-reported serious adverse events; does not establish this listing is compounded.
- Melanotan II tanning peptide products found to be inconsistently dosed Therapeutic Goods Administration, Australia (TGA) · Official regulator safety alert. Supports: TGA's testing findings on a specific set of seized nasal spray products and its warning that online product composition/quality can be uncertain; not testing of the listed vials.